FDA Accepts Huntington's Gene Therapy BLA, Sets May 1, 2027 Decision Date
QURE has more than doubled off its 52-week low of $8.73.
Summary
The FDA accepted uniQure's BLA for ifezuntirgene inilparvovec in Huntington's disease under the Accelerated Approval pathway and granted Priority Review, with a PDUFA target action date of May 1, 2027. This follows the September 2 BLA submission and comes after the September 29 data readout that sent shares down 48% premarket on 48-month Phase I/II results. If approved, this would be the first disease-modifying treatment for Huntington's disease, a market with roughly 75,000 patients across the U.S., EU and UK and no approved therapies. The FDA said it is tentatively planning to discuss the application at an Advisory Committee meeting, though no date is set — that panel is the key binary risk before the May 2027 decision. The confirmatory study design has been aligned with the FDA: it is randomized, enrolling about 200 patients in a 2:1 ratio, with Total Functional Capacity as the primary endpoint at 36 months, and the company plans to begin screening patients for it in the U.S. by the end of 2026.
Updated with an SEC 8-K filing · What changed
Updates
· SEC 8-K — Confirmatory study design aligned with FDA: randomized ~200 patients, 2:1 ratio, Total Functional Capacity primary endpoint at 36 months, screening in U.S. by end of 2026.
At the time of this announcement, QURE was trading at $27.66 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.7B. The 52-week trading range was $8.73 to $69.99. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.